Prikaz osnovnih podataka o dokumentu

dc.creatorMladenović, Minja
dc.creatorMorgan, Ibrahim
dc.creatorIlić, Nebojša
dc.creatorSaoud, Mohamad
dc.creatorPergal, Marija
dc.creatorKaluđerović, Goran N.
dc.creatorKnežević, Nikola Ž.
dc.date.accessioned2021-05-07T21:20:55Z
dc.date.available2021-05-07T21:20:55Z
dc.date.issued2021
dc.identifier.issn1999-4923
dc.identifier.urihttps://cer.ihtm.bg.ac.rs/handle/123456789/4572
dc.description.abstractRuthenium complexes are attracting interest in cancer treatment due to their potent cytotoxic activity. However, as their high toxicity may also affect healthy tissues, efficient and selective drug delivery systems to tumour tissues are needed. Our study focuses on the construction of such drug delivery systems for the delivery of cytotoxic Ru(II) complexes upon exposure to a weakly acidic environment of tumours. As nanocarriers, mesoporous silica nanoparticles (MSN) are utilized, whose surface is functionalized with two types of ligands, (2-thienylmethyl)hydrazine hydrochloride (H1) and (5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)hydrazine (H2), which were attached to MSN through a pH-responsive hydrazone linkage. Further coordination to ruthenium(II) center yielded two types of nanomaterials MSN-H1[Ru] and MSN-H2[Ru]. Spectrophotometric measurements of the drug release kinetics at different pH (5.0, 6.0 and 7.4) confirm the enhanced release of Ru(II) complexes at lower pH values, which is further supported by inductively coupled plasma optical emission spectrometry (ICP-OES) measurements. Furthermore, the cytotoxicity effect of the released metallotherapeutics is evaluated in vitro on metastatic B16F1 melanoma cells and enhanced cancer cell-killing efficacy is demonstrated upon exposure of the nanomaterials to weakly acidic conditions. The obtained results showcase the promising capabilities of the designed MSN nanocarriers for the pH-responsive delivery of metallotherapeutics and targeted treatment of cancer.sr
dc.language.isoensr
dc.publisherMDPIsr
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200358/RS//sr
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200026/RS//sr
dc.relationThe European Union’s Horizon 2020 research and innovation programme under grant agreement 952259 (NANOFACTS)sr
dc.relationThe German Academic Exchange Service (DAAD) [grant number: 57393212]sr
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/739570/EU//sr
dc.relation.isreferencedbyhttps://cer.ihtm.bg.ac.rs/handle/123456789/4573
dc.rightsopenAccesssr
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcePharmaceuticssr
dc.subjectCancer treatmentsr
dc.subjectControlled drug deliverysr
dc.subjectMesoporous silica nanoparticlessr
dc.subjectPH-responsive drug deliverysr
dc.subjectRuthenium-based anti-cancer drugssr
dc.titlePh-responsive release of ruthenium metallotherapeutics from mesoporous silica-based nanocarrierssr
dc.typearticlesr
dc.rights.licenseBYsr
dcterms.abstractМладеновић, Миња; Илић, Небојша; Пергал, Марија В.; Саоуд, Мохамад; Калуђеровић, Горан Н.; Кнежевић, Николић; Морган, Ибрахим;
dc.citation.volume13
dc.citation.issue4
dc.citation.spage460
dc.citation.rankM21~
dc.description.otherSupplementary material: [https://cer.ihtm.bg.ac.rs/handle/123456789/4573]
dc.identifier.pmid33800647
dc.identifier.doi10.3390/pharmaceutics13040460
dc.identifier.fulltexthttps://cer.ihtm.bg.ac.rs/bitstream/id/20166/pharmaceutics-13-00460-v3.pdf
dc.identifier.scopus2-s2.0-85103904375
dc.identifier.wos000643527200001
dc.type.versionpublishedVersionsr


Dokumenti

Thumbnail

Ovaj dokument se pojavljuje u sledećim kolekcijama

Prikaz osnovnih podataka o dokumentu